LSD1调控肿瘤免疫机制的研究进展

doi:10.16352/j.issn.1001-6325.2025.08.1088

基础医学与临床 ›› 2025, Vol. 45 ›› Issue (8): 1088-1092.doi: 10.16352/j.issn.1001-6325.2025.08.1088

LSD1调控肿瘤免疫机制的研究进展

龙丽娟^1#, 宋松泽^1,2#, 叶棋浓³, 蔺静^1,2*

1.解放军总医院第四医学中心检验科,北京 100048;
2.锦州医科大学第三临床医学院,辽宁锦州 121001;
3.军事科学院军事医学研究院生物工程研究所,北京 100850

收稿日期:2024-07-29 修回日期:2024-12-31 出版日期:2025-08-05 发布日期:2025-07-11
通讯作者: ^*lin_jing_bj@163.com
作者简介:^#对本文有相同贡献
基金资助:
国家自然科学基金(82330083)

Research progress of LSD1 in regulating tumor immune mechanisms

LONG Lijuan^1#, SONG Songze^1,2#, YE Qinong³, LIN Jing^1,2*

1. Department of Laboratory Medicine, the Fourth Medical Center of Chinese PLA General Hospital, Beijing 100048;
2. the Third Clinical Medical School, Jinzhou Medical University, Jinzhou 121001;
3. Institute of Biotechnology, Academy of Military Medical Sciences, Academy of Military Sciences, Beijing 100850, China

Received:2024-07-29 Revised:2024-12-31 Online:2025-08-05 Published:2025-07-11
Contact: ^*lin_jing_bj@163.com

摘要/Abstract

摘要： 赖氨酸特异性去甲基酶1(LSD1)在肿瘤免疫中具有调控作用,通过调节AGO2蛋白水平影响CD8⁺T细胞浸润;通过降低局部染色质可及性,参与正常B细胞增殖和分化。抑制LSD1通过恢复UL16结合蛋白表达,促进NK细胞对癌细胞的细胞毒性;LSD1通过调节SOD2水平影响M1巨噬细胞抵抗氧化应激;另外,调控LSD1表达能够影响CD19 CAR-T细胞和免疫检查点阻断剂的抗肿瘤功能。以LSD1为靶标的药物开发,将为肿瘤的免疫治疗提供新思路。

关键词: 赖氨酸特异性去甲基酶1, 肿瘤免疫, 免疫治疗, 肿瘤微环境, 免疫检查点

Abstract: Lysine-specific demethylase 1(LSD1) plays a regulatory role in tumor immunity. LSD1 affects CD8⁺T cell infiltration by regulating AGO2 protein level, and it is required for normal B cell proliferation and differentiation via reducing local chromatin accessibility. LSD1 inhibition promotes NK cell cytotoxicity of cancer cells through restoring the expression of ULBPs. LSD1 affects the resistance of M1 macrophages to oxidative stress by regulating the level of SOD2; In addition, regulating the expression of LSD1 affects the anti-tumor function of CD19 CAR-T cells and immune checkpoint blockers. The development of drugs targeting LSD1 will provide new ideas for immunotherapy of tumors.

Key words: LSD1, tumor immunity, immunotherapy, tumor microenvironment, immune checkpoint

中图分类号:

R392.1

龙丽娟, 宋松泽, 叶棋浓, 蔺静. LSD1调控肿瘤免疫机制的研究进展[J]. 基础医学与临床, 2025, 45(8): 1088-1092.

LONG Lijuan, SONG Songze, YE Qinong, LIN Jing. Research progress of LSD1 in regulating tumor immune mechanisms[J]. Basic & Clinical Medicine, 2025, 45(8): 1088-1092.

参考文献

[1] Lee DY, Salahuddin T, Iqbal J.Lysine-specific demethylase 1 (LSD1)-mediated epigenetic modification of immunogenicity and immunomodulatory effects in breast cancers[J]. Curr Oncol, 2023, 30:2127-2143.
[2] Doi K, Murata K, Ito S, et al. Role of lysine-specific demethylase 1 in metabolically integrating osteoclast differentiation and inflammatory bone resorption through hypoxia-inducible factor 1α and E2F1[J]. Arthritis Rheumatol, 2022, 74:948-960.
[3] Mamun MAA, Zhang Y, Zhao JY, et al. LSD1: an emerging face in altering the tumor microenvironment and enhancing immune checkpoint therapy[J]. J Biomed Sci, 2023, 30:60. doi: 10.1186/s12929-023-00952-0.
[4] Giles JR, Globig AM, Kaech SM, et al. CD8⁺T cells in the cancer-immunity cycle[J]. Immunity, 2023, 56:2231-2253.
[5] Sheng W, Lafleur MW, Nguyen TH, et al. LSD1 ablation stimulates anti-tumor immunity and enables checkpoint blockade[J]. Cell, 2018, 174:549-563 e19. doi:10.1016/j.cell.2018.05.052.
[6] Liu Y, Debo B, Li M, et al. LSD1 inhibition sustains T cell invigoration with a durable response to PD-1 blockade[J]. Nat Commun, 2021, 12:6831. doi:10.1038/s41467-021-27179-7.
[7] Shen DD, Pang JR, Bi YP, et al. LSD1 deletion decreases exosomal PD-L1 and restores T-cell response in gastric cancer[J]. Mol Cancer, 2022, 21:75. doi:10.1186/s12943-022-01557-1.
[8] Hiatt JB, Sandborg H, Garrison SM, et al. Inhibition of LSD1 with bomedemstat sensitizes small cell lung cancer to immune checkpoint blockade and T-cell killing[J]. Clin Cancer Res, 2022, 28:4551-4564.
[9] Qin Y, Vasilatos SN, Chen L, et al. Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade[J]. Oncogene, 2019, 38:390-405.
[10] Song S, Zhang D, Chen J, et al. CHMP4A stimulates CD8⁺T-lymphocyte infiltration and inhibits breast tumor growth via the LSD1/IFNβ axis[J]. Cancer Sci, 2023, 114:3162-3175.
[11] Bryushkova EA, Mushenkova NV, Turchaninova MA, et al. B cell clonality in cancer[J]. Semin Immunol, 2024, 72:101874. doi:10.1016/j.smim.2024.101874.
[12] Haines RR, Barwick BG, Scharer CD, et al. The histone demethylase LSD1 regulates B cell proliferation and plasmablast differentiation[J]. J Immunol, 2018, 201:2799-2811.
[13] Liu M, Du M, Yu J, et al. CEBPA mutants down-regulate AML cell susceptibility to NK-mediated lysis by disruption of the expression of NKG2D ligands, which can be restored by LSD1 inhibition[J]. Oncoimmunology, 2022, 11:2016158. doi:10.1080/2162402X.2021.2016158.
[14] Bailey CP, Fiueroa M, Gangadharan A, et al. Pharmacologic inhibition of lysine-specific demethylase 1 as a therapeutic and immune-sensitization strategy in pediatric high-grade glioma[J]. Neuro Oncol, 2020, 22:1302-1314.
[15] Boutilier AJ, Elsawa SF. Macrophage polarization states in the tumor microenvironment[J]. Int J Mol Sci, 2021, 22:6995. doi:10.3390/ijms22136995.
[16] Tokarz P, Plosaz T, Regdon Z, et al. PARP1-LSD1 functional interplay controls transcription of SOD2 that protects human pro-inflammatory macrophages from death under an oxidative condition[J]. Free Radic Biol Med, 2019, 131:218-224.
[17] Jogalekar MP, Rajendran RL, Khan F, et al. CAR T-cell-based gene therapy for cancers: new perspectives, challenges, and clinical developments[J]. Front Immunol, 2022, 13:925985. doi:10.3389/fimmu.2022.925985.
[18] González Barca E. Role of bispecific antibodies in relapsed/refractory diffuse large B-Cell lymphoma in the CART Era[J]. Front Immunol, 2022, 13:909008. doi:10.3389/fimmu.2022.909008.
[19] Si Lim SJ, Grupp SA, DiNofia AM. Tisagenlecleucel for treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia[J]. Pediatr Blood Cancer, 2021, 68:e29123. doi:10.1002/pbc.29123.
[20] Zhang J, Zhu J, Zheng G, et al. Co-expression of miR155 or LSD1 shRNA increases the anti-tumor functions of CD19 CAR-T cells[J]. Front Immunol, 2021, 12:811364. doi:10.3389/fimmu.2021.811364.
[21] Gao M, Shi J, Xiao X, et al. PD-1 regulation in immune homeostasis and immunotherapy[J]. Cancer Lett, 2024, 588:216726. doi:10.1016/j.canlet.2024.216726.
[22] Han Y, Xu S, Ye W, et al. Targeting LSD1 suppresses stem cell-like properties and sensitizes head and neck squamous cell carcinoma to PD-1 blockade[J]. Cell Death Dis, 2021, 12:993. doi:10.1038/s41419-021-04297-0.
[23] Sheng W, Liu Y, Chakraborty D, et al. Simultaneous inhibition of LSD1 and TGFβ enables eradication of poorly immunogenic tumors with anti-PD-1 treatment[J]. Cancer Discov, 2021, 11:1970-1981.
[24] Noce B, Di Bello E, Fioravanti R, et al. LSD1 inhibitors for cancer treatment: focus on multi-target agents and compounds in clinical trials[J]. Front Pharmacol, 2023, 14:1120911. doi:10.3389/fphar.2023.1120911.

LSD1调控肿瘤免疫机制的研究进展

Research progress of LSD1 in regulating tumor immune mechanisms

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	乔雯华, 许依, 董鹏, 何维, 陈慧, 张建民. 基因工程化iNK^{NKG2A KO}细胞具有HLA-E特异的抗肿瘤活性[J]. 基础医学与临床, 2025, 45(5): 599-607.
[2]	李云帆, 邹佳铭, 王钰铖, 鞠瑞, 郭磊. CTO抑制小鼠胶质瘤细胞原位生长并调节相关小胶质细胞代谢及炎性表型[J]. 基础医学与临床, 2025, 45(4): 478-485.
[3]	聂牧文, 孙昭, 李宁宁, 赵林, 白春梅. 原发性心包间皮瘤的临床特征与预后[J]. 基础医学与临床, 2025, 45(2): 222-228.
[4]	刘保清, 黄容, 卢艳, 李凯, 张宁, 刘长征, 宋伟. 胃癌类器官在基础研究与临床应用中的进展[J]. 基础医学与临床, 2024, 44(9): 1219-1222.
[5]	李阳, 朱蕾. 真核延伸因子2激酶是治疗肿瘤的潜在新靶标[J]. 基础医学与临床, 2024, 44(7): 1039-1043.
[6]	周玥, 童安莉. 嗜铬细胞瘤/副神经节瘤免疫微环境[J]. 基础医学与临床, 2024, 44(6): 742-747.
[7]	刘宛榕, 赵林. 颅内生殖细胞肿瘤的药物治疗[J]. 基础医学与临床, 2024, 44(10): 1350-1356.
[8]	葛郁平, 刘莹, 赵林. 血管肉瘤药物治疗进展[J]. 基础医学与临床, 2024, 44(10): 1363-1367.
[9]	杨俊豪, 赵林. 恶性间皮瘤的靶向与免疫治疗[J]. 基础医学与临床, 2024, 44(10): 1342-1349.
[10]	颜晨红, 金儿. 外泌体PD-L1在非小细胞肺癌诊断和治疗上的研究进展[J]. 基础医学与临床, 2023, 43(9): 1457-1461.
[11]	代娣, 刘玉琴. 原发性胃淋巴瘤的诊断难点及治疗进展[J]. 基础医学与临床, 2023, 43(9): 1462-1466.
[12]	伍琦, 王绍波. CRISPR/Cas9技术在CAR-T细胞治疗肿瘤中作用的研究进展[J]. 基础医学与临床, 2023, 43(8): 1313-1316.
[13]	陈忠婕, 黄嘉如, 胡清, 赵珍琴, 陈俏俏, 孙浚源, 贾静. 免疫检查点CD276蛋白参与肿瘤发生发展作用机制的研究进展[J]. 基础医学与临床, 2023, 43(7): 1143-1147.
[14]	杜风, 陈翌阳, 张楠, 徐俊玄, 宁婷婷, 朱圣韬, 张澍田. FOXL2NB在结直肠癌中的表达和临床意义[J]. 基础医学与临床, 2023, 43(6): 909-915.
[15]	张海灵, 杨玉, 周倩倩, 汪远金, 王婷. 微囊藻毒素-LR处理的中性粒细胞NETs促进结直肠癌细胞迁移[J]. 基础医学与临床, 2023, 43(6): 967-973.